Dual Receptor Agonist for Type 2 Diabetes

Treatment with LY3298176, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist, resulted in better glucose control than dulaglutide, a GLP-1 receptor agonist, reported a phase 2 trial in the Lancet.